(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 5.18% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 10.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Becton Dickinson & Co's revenue in 2025 is $20,640,000,000.On average, 8 Wall Street analysts forecast BDX's revenue for 2025 to be $6,276,119,891,592, with the lowest BDX revenue forecast at $6,245,482,542,171, and the highest BDX revenue forecast at $6,349,264,768,737. On average, 8 Wall Street analysts forecast BDX's revenue for 2026 to be $6,578,495,886,468, with the lowest BDX revenue forecast at $6,525,152,442,225, and the highest BDX revenue forecast at $6,633,402,495,942.
In 2027, BDX is forecast to generate $6,900,586,886,485 in revenue, with the lowest revenue forecast at $6,831,525,936,432 and the highest revenue forecast at $6,995,480,261,823.